Trio of biotechs raise funds to make enzymes and develop drugs for IBS and other autoimmune diseases

Huili Bio, a Hong Kong-based biotech, has reeled in “hundreds of million RMB,” which equates to at least $15 million, in a Series A financing.

The four-year-old startup is using synthetic biology to computationally design enzymes. The financing round will bankroll hiring, research and development for “new product pipelines” and ramp up the construction of “large-scale production facilities,” the company said Thursday.